Contribute Try STAT+ Today

The great hope of artificial intelligence in breast cancer is that it can distinguish harmless lesions from those likely to become malignant. By scanning millions of pixels, AI promises to help physicians find an answer for every patient far sooner, offering them freedom from anxiety or a better chance against a deadly disease.

But the Food and Drug Administration’s decision to grant clearances to these products without requiring them to publicly disclose how extensively their tools have been tested on people of color threatens to worsen already gaping disparities in outcomes within breast cancer, a disease which is 46% more likely to be fatal for Black women.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.